✦ LIBER ✦

Corrigendum to “A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study” [Gynecol. Oncol. 116 (2010)]

✍ Scribed by Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie Small; Jacob Rotmensch; Robert S. Mannel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of mifepristone in

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Phase II Trial of Bevacizumab in Persist

✍ Burger, R. A.; Sill, M. W.; Monk, B. J.; Greer, B. E.; Sorosky, J. I. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 112 KB

Phase II evaluation of dasatinib in the

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II evaluation of lapatinib in th

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

A phase II evaluation of AMG 102 (rilotu

✍ Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 246 KB

A phase II study of vorinostat in the tr

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB